Home › Trials › NCT04212494

Thrombus aspiration for heart attack patients with high thrombus burden

Thrombus Aspiration in Primary Percutaneous Coronary Intervention for STEMI Patients With High Thrombus Burden

Not applicable Interventional Guangdong Provincial People's Hospital · NCT04212494

This study tests if using a special technique to remove blood clots can help heart attack patients with a lot of clots feel better and avoid serious problems after treatment.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment3838 (estimated)
Ages18 Years and up
SexAll
SponsorGuangdong Provincial People's Hospital Academic / other
Locations50 sites (Fuzhou, Fujian and 49 other locations)
Trial IDNCT04212494 on ClinicalTrials.gov

What this trial studies

This study investigates the effectiveness of thrombus aspiration in patients experiencing ST-segment Elevation Myocardial Infarction (STEMI) with a high thrombus burden during primary percutaneous coronary intervention (PCI). It is a multicenter, open-label, randomized controlled trial where participants are assigned to receive either thrombus aspiration or standard PCI treatment. The goal is to determine if thrombus aspiration can reduce the risk of serious cardiovascular events within 180 days and stroke within 30 days after treatment.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older who are experiencing STEMI and can undergo primary PCI within 12 hours of symptom onset.

Not a fit: Patients who are hemodynamically unstable, have undergone thrombolytic therapy, or have a predicted survival time of less than 6 months due to non-cardiac disease may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly lower the risk of severe complications for STEMI patients with high thrombus burden.

How similar studies have performed: Previous studies have shown varying results with thrombus aspiration in similar patient populations, indicating that while the approach has been tested, its efficacy in this specific context remains to be fully established.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Age ≥ 18 years;
2. STEMI patients undergoing primary PCI within 12 hours after the onset of symptoms;
3. High thrombus burden after guidewire passes the lesion (TIMI thrombus grade ≥3);
4. Informed consent must be voluntary;

Exclusion Criteria:

1. Haemodynamic instability or cardiogenic shock;
2. After thrombolytic therapy;
3. The predicted survival time is less than 6 months due to non-cardiac disease;
4. History of coronary artery bypass grafting;
5. Participate in other researches within 30 days;
6. Preoperative gastrointestinal bleeding or contraindications to dual antiplatelet therapy;
7. Patients were considered unsuitable by other researchers.

Where this trial is running

Fuzhou, Fujian and 49 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions ST-segment Elevation Myocardial InfarctionThrombus AspirationCoronary InterventionThrombus Burden
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.